Sionna Therapeutics, Inc.
SION- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002036042
In the last 90 days, Sionna Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 146 institutions reported holding it in 13F filings for Q2 2026, worth $2.11B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 10, 2026
- $167.3M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $21.8M in total
- 1
- 13F holdersQ2 2026, +25 vs. previous quarter
- 146
- 13F valueReported value at the end of Q2 2026
- $2.11B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$75.3M
- No comparable prior period
- Free cash flow, FY2025
- -$66.7M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 3.68M
- Shares sold short
- Change
- −121.2K
- −3.2% vs. previous
- Days to cover
- 3.74
- At average daily volume
Superinvestors holding SION, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Sionna Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.4%
Sionna Therapeutics, Inc.'s share of the portfolio
- Shares
- 3,195,181
- Value
- $140.6M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Sionna Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 (view filing)6:56 PM ET | Sep 17 | 4 days | RA Capital Healthcare Fund LP and 5 othersDirector | SSale | −3.45M | $6.33 | −$21.8M | −50.0%3.45M after | 2 lots |
| Jul 9, 2026 (view filing)4:47 PM ET | Jul 7 | 2 days | Thompson Peter A.Director | SSale | −85.9K | $44.86 | −$3.85M | −3.4%2.47M after | 10b5-1Duplicate filing |
| Jul 9, 2026 (view filing)4:44 PM ET | Jul 7 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −85.9K | $44.86 | −$3.85M | −3.4%2.47M after | 10b5-1 |
| Jul 7, 2026 (view filing)4:38 PM ET | Jul 6 | 1 day | Fitzpatrick JenniferChief Legal Officer | SSale | −10.3K | $43.60 | −$446.9K | −100.0%0 after | 10b5-1 |
| Jul 2, 2026 (view filing)4:45 PM ET | Jun 30 | 2 days | Thompson Peter A.Director | SSale | −115.8K | $45.50 | −$5.27M | −4.3%2.56M after | 10b5-1Duplicate filing |
| Jul 2, 2026 (view filing)4:42 PM ET | Jun 30 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −115.8K | $45.50 | −$5.27M | −4.3%2.56M after | 10b5-1 |
| May 29, 2026 (view filing)8:57 PM ET | May 27 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −101 | $44.49 | −$4.49K | 0.0%2.67M after | 10b5-1Duplicate filing |
| May 29, 2026 (view filing) | May 27 | 2 days | Thompson Peter A.Director | SSale | −101 | $44.49 | −$4.49K | 0.0%2.67M after | 10b5-1 |
| May 11, 2026 (view filing)6:58 PM ET | May 7-11 | 4 days | OrbiMed Advisors LLC and 1 otherDirector | SSale | −293.0K | $45.62 | −$13.4M | −9.9%2.67M after | 3 lots10b5-1Duplicate filing |
| May 11, 2026 (view filing) | May 7-11 | 4 days | Thompson Peter A.Director | SSale | −293.0K | $45.62 | −$13.4M | −9.9%2.67M after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 146 holdersThe largest institutional positions in Sionna Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 9,905,045 | $435.7M | 3.79% | 00.0% | Unchanged |
| TPG GP A, LLC | 6,494,962 | $285.7M | 5.71% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,195,181 | $140.6M | 0.40% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 2,995,602 | $131.8M | 14.95% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,555,877 | $112.4M | 2.13% | −974,825−27.6% | Reduced |
| Enavate Sciences GP, LLC | 2,478,030 | $109.0M | 31.56% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,600,000 | $70.4M | 0.10% | +1,450,000+966.7% | Added |
| BlackRock, Inc. | 1,474,769 | $64.9M | 0.00% | +178,902+13.8% | Added |
| JPMorgan Chase & Co | 1,490,508 | $64.1M | 0.00% | +25,494+1.7% | Added |
| Jennison Associates LLC | 1,172,133 | $51.6M | 0.03% | −279,087−19.2% | Reduced |
Holders of 5% or more of SION
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Sionna Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| TPG GP A, LLC | 13D | 15.20%6.68M shares | New | Feb 18, 20251 filing | Feb 18, 2025 | SEC |
| Ra Capital Management, L.P. | 13D/A | 14.30%6.48M shares | −8.30 ppfrom 22.60% | Feb 18, 20253 filings | Sep 21, 2026 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G/A | 7.10%3.20M shares | +0.40 ppfrom 6.70% | Feb 14, 20252 filings | May 15, 2026 | SEC |
| OrbiMed Advisors LLC | 13D/A | 6.60%2.97M shares | −1.80 ppfrom 8.40% | Feb 13, 20252 filings | Apr 20, 2026 | SEC |
| Goldman Sachs Group Inc | 13G | 5.80%2.64M shares | New | Nov 9, 20261 filing | Nov 9, 2026 | SEC |